Ketorolac (Toradol) Clinical Guidelines and Safety Considerations

Renal Monitoring Recommendations

The National Comprehensive Cancer Network (NCCN) advises obtaining baseline blood urea nitrogen (BUN) and serum creatinine values before starting ketorolac in elderly or renally‑impaired patients, and repeating these tests if therapy extends beyond the acute setting. 1

Patients aged ≥ 60 years have a higher incidence of gastrointestinal, renal, and cardiac toxicity when treated with ketorolac. 1
In individuals with cardiovascular disease, ketorolac may worsen hypertension and increase bleeding risk when used with anticoagulants. 2
History of peptic ulcer disease, significant alcohol intake (≥ 2 drinks/day), or hepatic dysfunction elevates the risk of adverse gastrointestinal events with ketorolac. 3
Renal impairment—especially when accompanied by volume depletion or concurrent nephrotoxic drugs such as cyclosporine or cisplatin—requires heightened caution due to increased nephrotoxicity risk. 1
Patients with bleeding disorders or thrombocytopenia are susceptible to impaired platelet function because ketorolac reversibly inhibits platelet aggregation. 2

Ketorolac is contraindicated in patients with NSAID‑induced asthma. 4
Use of ketorolac is prohibited in individuals who have experienced a recent cerebrovascular hemorrhage. 4
Active peptic ulcer disease or ongoing gastrointestinal bleeding constitute absolute contraindications to ketorolac therapy. 3

NCCN guidelines recommend a ketorolac dose of 15–30 mg IV every 6 hours for short‑term cancer pain control, with a maximum treatment duration of 5 days. 5

The Society of Critical Care Medicine (SCCM) recommends an initial 30 mg IM or IV dose of ketorolac in ICU patients, followed by 15–30 mg every 6 hours, not exceeding 120 mg per day. 6

The American Society of Anesthesiologists advises that ketorolac should be incorporated into multimodal analgesia regimens using the minimum effective dose, and cautions that continuous infusion may lead to drug accumulation and increased toxicity. 7

A 50 % dose reduction (maximum 60 mg per day) is required for patients who are ≥ 65 years old, weigh < 50 kg, have moderate renal impairment, or are receiving other nephrotoxic agents. 8

According to the KDOQI guidelines, NSAIDs—including ketorolac—should be avoided in patients with an estimated GFR < 30 mL/min/1.73 m², and prolonged therapy is not recommended when GFR < 60 mL/min/1.73 m². 8